Clinical Trial

Evaluation of the Safety, Tolerability and Pharmacokinetics of HY8931 in Healthy Adult Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn the safety, tolerability and pharmacokinetics of single and multiple doses of HY8931 in healthy adult participants. The main questions it aims to answer are: * How is the safety and tolerability following administration of single and multiple doses of HY8931 in healthy adult participants? * What is the PK character of HY8931 following administration of single and multiple doses of HY8931 in healthy adult participants? Researchers will compare HY8931 to a placebo (a look-alike substance that contains no drug) to see if HY8931 is safe and well tolerated. Participants will take HY8931 or a placebo once or twice in single dose group or multiple dose group. And will be follow-up until Day 90.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-12-01; most recent amendment 2026-03-09.
Status change: Not Yet Recruiting → Recruiting 2026-03-02
Trial Details
NCT Number NCT07281703
Lead Sponsor Newsoara Biopharma Co., Ltd.
Conditions Healthy
Enrollment 60 participants
Start Date 2026-01-14
Primary Completion 2026-09 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-03-11